News und Analysen

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the fourth-quarter and full-year 2020 and provided guidance for 2021. For the quarter, revenue was $791.0

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it has signed a definitive agreement to acquire Cognate BioServices, Inc., a premier, cell and gene therapy contract

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced strong results of operations for the fourth quarter and full-year 2020, exceeding the goals for net sales and adjusted earnings per

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute starke Ergebnisse der operativen Tätigkeit für das vierte Quartal und das Gesamtjahr 2020 bekannt. Das Unternehmen hat seine Ziele

Novocure (NASDAQ: NVCR) has announced an addition to its board of directors. Timothy J. Scannell, an experienced executive leader, was elected to Novocure’s board on Feb. 5.

“We are extremely

Premier Inc. (NASDAQ: PINC), through its ProvideGx^® program, has partnered with Apotex Corp. to supply three essential antibiotics to healthcare providers, helping to secure the immediate and

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced

Chemed Corporation (NYSE:CHE) today announced that it will release financial results for the fourth quarter ended December 31, 2020, on Tuesday, February 23, 2021, following the close of trading on

AMN Healthcare (NYSE: AMN) received a top ranking – 95 out of 100 – in the Human Rights Campaign Foundation’s 2021 Corporate Equality Index, the nation’s foremost survey measuring corporate

Premier, Inc. (NASDAQ: PINC) today reported financial results for the fiscal year (FY) 2021 second quarter ended December 31, 2020 and announced its fiscal 2021 financial guidance.

All results

Premier Inc. (NASDAQ: PINC) today announced that after nearly 18 years of distinguished service, Susan DeVore is retiring as the company’s chief executive officer and a member of its Board of

Regulatory News:

Vifor Pharma today announced that the Board of Directors will propose Dr Alexandre LeBeaut for election to the Board at the next Annual General Meeting on 6 May 2021.

Jacques

AMN Healthcare (NYSE: AMN) is one of 380 companies across 11 industry sectors and 44 countries included in the 2021 Bloomberg Gender-Equality Index (GEI). In the healthcare sector, AMN Healthcare

QIAGEN gab heute bekannt, dass das wachsende Portfolio an COVID-19-Produkten um Kits für Abwassertests ergänzt wird. Der Einsatz der Digitalen PCR (dPCR) bei der weltweiten Überwachung von COVID-19

QIAGEN today announced the addition of kits for wastewater testing to its growing portfolio of COVID-19 products. The use of dPCR in the worldwide surveillance of COVID-19 is an additional step

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with Cypre, Inc., a biotechnology company that is using 3D hydrogel

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the fourth quarter and full-year 2020 on Tuesday, February 9,at

Premier, Inc. (NASDAQ: PINC), a leading healthcare improvement company, today announced that its Board of Directors declared a cash dividend of $0.19 per share of Class A common stock issued and

Premier Inc. (NASDAQ: PINC), through its ProvideGx® program, has partnered with Pfizer Inc. to supply five essential medications to healthcare providers, helping to meet the immediate and long-term

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections – and will

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it plans to resubmit in the first quarter of 2021 its QIAreach SARS-CoV-2 Antigen Test to the U.S. Food and Drug

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute Pläne bekannt, den QIAreach SARS-CoV-2 Antigen Test zum im ersten Quartal 2021 in den USA erneut zur Notfallzulassung (EUA) bei der

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) gab heute bekannt, dass die Genauigkeit und Effektivität seiner Polymerase-Kettenreaktionstests (PCR) für den Nachweis von

LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth quarter and full-year 2020 results on Wednesday, February